Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03258931 |
Recruitment Status :
Recruiting
First Posted : August 23, 2017
Last Update Posted : May 22, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Newly Diagnosed FLT3 Mutated AML | Drug: Crenolanib Drug: Midostaurin Drug: Cytarabine Drug: Duanorubicin | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 510 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia |
Actual Study Start Date : | August 15, 2018 |
Estimated Primary Completion Date : | November 2022 |
Estimated Study Completion Date : | November 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Crenolanib
Crenolanib following salvage chemotherapy
|
Drug: Crenolanib
Crenolanib will be administered orally
Other Name: Crenolanib besylate Drug: Cytarabine 100 mg/m² IV continuous infusion over 24 hours Drug: Duanorubicin 90 mg/m2 IV |
Active Comparator: Midostaurin
Midostaurin following salvage chemotherapy
|
Drug: Midostaurin
Midostaurin will be administered orally Drug: Cytarabine 100 mg/m² IV continuous infusion over 24 hours Drug: Duanorubicin 90 mg/m2 IV |
- Event-free survival (EFS) [ Time Frame: 5 years ]
- Overall Survival [ Time Frame: 7 years ]
- Relapse free survival [ Time Frame: 5 years ]
- Composite complete remission rate [ Time Frame: 5 years ]
- Duration of response [ Time Frame: 5 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Confirmed diagnosis of de novo AML according to World Health Organization (WHO) 2016 classification
- Presence of FLT3-ITD and/or D835 mutation(s) in bone marrow or peripheral blood
- Age ≥ 18 years and ≤ 60 years
- Adequate hepatic function within 48 hours prior to induction chemotherapy
- Adequate renal functions within 48 hours prior to induction chemotherapy
- ECOG performance status within 48 hours prior to induction chemotherapy ≤ 3
- Eligible for intensive cytarabine/daunorubicin (7+3) chemotherapy specified
Exclusion Criteria:
- Acute promyelocytic leukemia (APL)
- Known clinically active central nervous system (CNS) leukemia
- Severe liver disease
- Active infections
- Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Known infection with human immunodeficiency virus (HIV)
- Prior systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors, immunotherapy, or investigational agents)(except for hydroxyurea and/or leukapheresis)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03258931
Contact: General Contact | 214-593-0500 | info@arogpharma.com |
Responsible Party: | Arog Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT03258931 |
Other Study ID Numbers: |
ARO-021 |
First Posted: | August 23, 2017 Key Record Dates |
Last Update Posted: | May 22, 2020 |
Last Verified: | May 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Cytarabine Midostaurin Crenolanib Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Antiviral Agents Anti-Infective Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Protein Kinase Inhibitors Enzyme Inhibitors |